Intrust Bank NA Sells 83 Shares of argenex SE $ARGX

Intrust Bank NA reduced its holdings in shares of argenex SE (NASDAQ:ARGX) by 11.7% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 627 shares of the company’s stock after selling 83 shares during the period. Intrust Bank NA’s holdings in argenex were worth $346,000 at the end of the most recent reporting period.

Several other hedge funds have also bought and sold shares of ARGX. Lord Abbett & CO. LLC grew its holdings in argenex by 33.2% in the first quarter. Lord Abbett & CO. LLC now owns 274,700 shares of the company’s stock worth $162,585,000 after purchasing an additional 68,498 shares during the period. Millennium Management LLC boosted its position in shares of argenex by 316.9% in the 1st quarter. Millennium Management LLC now owns 268,604 shares of the company’s stock worth $158,977,000 after purchasing an additional 204,180 shares in the last quarter. Jennison Associates LLC grew its stake in shares of argenex by 6.1% in the 2nd quarter. Jennison Associates LLC now owns 264,647 shares of the company’s stock worth $145,879,000 after buying an additional 15,186 shares during the last quarter. Allspring Global Investments Holdings LLC increased its position in argenex by 4.8% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 184,987 shares of the company’s stock valued at $100,350,000 after buying an additional 8,537 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its stake in argenex by 14.8% during the first quarter. Goldman Sachs Group Inc. now owns 168,765 shares of the company’s stock valued at $99,886,000 after buying an additional 21,805 shares during the last quarter. Institutional investors own 60.32% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on ARGX. Weiss Ratings reissued a “hold (c)” rating on shares of argenex in a research note on Wednesday, October 8th. Wedbush upped their price target on shares of argenex from $880.00 to $1,000.00 and gave the stock an “outperform” rating in a research note on Friday, November 14th. Guggenheim restated a “buy” rating and set a $1,070.00 price objective on shares of argenex in a research note on Thursday, September 18th. TD Cowen lifted their target price on shares of argenex from $800.00 to $1,146.00 and gave the stock a “buy” rating in a report on Friday, October 31st. Finally, Royal Bank Of Canada increased their price target on shares of argenex from $850.00 to $860.00 and gave the company an “outperform” rating in a report on Friday, October 31st. One research analyst has rated the stock with a Strong Buy rating, nineteen have given a Buy rating and three have issued a Hold rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $903.78.

argenex Stock Performance

Shares of NASDAQ:ARGX opened at $918.53 on Wednesday. The firm has a market cap of $56.55 billion, a price-to-earnings ratio of 39.44, a price-to-earnings-growth ratio of 0.95 and a beta of 0.45. The business has a 50-day simple moving average of $805.61 and a two-hundred day simple moving average of $676.75. argenex SE has a fifty-two week low of $510.05 and a fifty-two week high of $934.13.

argenex (NASDAQ:ARGX) last announced its quarterly earnings results on Thursday, October 30th. The company reported $4.40 EPS for the quarter, topping analysts’ consensus estimates of $4.37 by $0.03. argenex had a net margin of 41.58% and a return on equity of 29.78%. The firm had revenue of $1.12 billion during the quarter, compared to analyst estimates of $1.07 billion. As a group, research analysts predict that argenex SE will post 3.13 earnings per share for the current year.

argenex Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.